This trial will investigate whether tDCS to the cerebellum is safe and effective in treating symptoms of ASD such as repetitive behaviors and hyperactivity.
1 Primary · 6 Secondary · Reporting Duration: Pre-Intervention at 1 week and Post-Intervention at 1 week and 1 month
Experimental Treatment
Non-Treatment Group
60 Total Participants · 2 Treatment Groups
Primary Treatment: tDCS · Has Placebo Group · N/A
Age 4 - 17 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Pennsylvania | 40.0% |
Texas | 20.0% |
New York | 20.0% |
Other | 20.0% |
< 18 | 66.7% |
18 - 65 | 33.3% |
Children's Medical Center | 100.0% |
Met criteria | 66.7% |
Did not meet criteria | 33.3% |